Rimegepant sulfate is a small molecule, highly selective calcitonin gene-related peptide antagonist (CGRP) developed by Biohaven Pharmaceutical Holdings, Inc. and approved by the FDA for the acute treatment of migraine. rimegepant and ubrogepant are the only CGRP antagonists with oral bioavailability. Because of the absence of vasoconstrictive properties observed with oral CGRP antagonists, the use of rimegepant is safer and more reliable in patients with contraindications to standard therapy[1].
Rimegepant sulfate is indicated for the acute treatment of migraine and for the preventive treatment of episodic migraine in adults.
Remegipam sulfate is used for the acute treatment of migraine by antagonizing CGRP receptors, reducing CGRP-induced vasodilation and pain signal transmission.
Common side effects of Rimegepant sulfate are nausea, which may be severe enough to cause shortness of breath, difficulty breathing; swelling of the face, eyes, mouth, throat, tongue, or lips; rash, measles; and itching.
Rimegepant sulfate is prepared by the reaction of rimegepant and water.
Step: With sulfuric acid In ethanol at 20 - 70℃; Solvent; Temperature.
[1] J S. Rimegepant: First Approval.[J]. Drugs, 2020, 80 7: 741-746. DOI:10.1007/s40265-020-01301-3.
